United Therapeutics Co. (NASDAQ:UTHR – Get Rating) CEO Martine A. Rothblatt sold 8,000 shares of the firm's stock in a transaction on Friday, January 13th. The shares were sold at an average price of $261.52, for a total transaction of $2,092,160.00. Following the sale, the chief executive officer now owns 130 shares in the company, valued at approximately $33,997.60. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
United Therapeutics Trading Down 0.6 %
United Therapeutics stock traded down $1.54 during trading hours on Wednesday, reaching $259.56. The stock had a trading volume of 286,221 shares, compared to its average volume of 401,356. The stock has a market cap of $11.83 billion, a PE ratio of 17.65, a PEG ratio of 1.54 and a beta of 0.62. United Therapeutics Co. has a 52 week low of $158.38 and a 52 week high of $283.09. The company has a debt-to-equity ratio of 0.18, a current ratio of 9.68 and a quick ratio of 9.39. The company has a fifty day simple moving average of $270.88 and a 200-day simple moving average of $240.79.
Get United Therapeutics alerts:United Therapeutics (NASDAQ:UTHR – Get Rating) last announced its quarterly earnings results on Wednesday, November 2nd. The biotechnology company reported $4.91 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.57 by $1.34. The business had revenue of $516.00 million for the quarter, compared to analyst estimates of $492.92 million. United Therapeutics had a net margin of 38.03% and a return on equity of 16.63%. Analysts forecast that United Therapeutics Co. will post 16.63 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research firms have recently weighed in on UTHR. JPMorgan Chase & Co. raised their price objective on shares of United Therapeutics from $240.00 to $265.00 and gave the company an "overweight" rating in a research report on Thursday, November 3rd. Argus lifted their target price on shares of United Therapeutics from $250.00 to $300.00 and gave the stock a "buy" rating in a research report on Wednesday, January 11th. The Goldman Sachs Group initiated coverage on shares of United Therapeutics in a research report on Monday, December 5th. They issued a "sell" rating and a $230.00 target price on the stock. StockNews.com upgraded shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Thursday, November 3rd. Finally, Oppenheimer lifted their target price on shares of United Therapeutics from $325.00 to $375.00 and gave the stock an "outperform" rating in a research report on Thursday, November 3rd. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $283.64.Institutional Investors Weigh In On United Therapeutics
A number of large investors have recently added to or reduced their stakes in UTHR. Wellington Management Group LLP boosted its stake in shares of United Therapeutics by 73.7% during the 1st quarter. Wellington Management Group LLP now owns 1,675,414 shares of the biotechnology company's stock valued at $300,585,000 after purchasing an additional 710,668 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in shares of United Therapeutics by 205.7% during the 2nd quarter. Assenagon Asset Management S.A. now owns 641,656 shares of the biotechnology company's stock valued at $151,200,000 after purchasing an additional 431,739 shares in the last quarter. Deutsche Bank AG boosted its stake in shares of United Therapeutics by 1,011.5% during the 2nd quarter. Deutsche Bank AG now owns 196,876 shares of the biotechnology company's stock valued at $46,393,000 after purchasing an additional 179,163 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of United Therapeutics by 3.8% during the 3rd quarter. Vanguard Group Inc. now owns 4,411,616 shares of the biotechnology company's stock valued at $923,703,000 after purchasing an additional 163,542 shares in the last quarter. Finally, Farallon Capital Management LLC boosted its stake in shares of United Therapeutics by 40.0% during the 3rd quarter. Farallon Capital Management LLC now owns 549,673 shares of the biotechnology company's stock valued at $115,091,000 after purchasing an additional 156,977 shares in the last quarter. Institutional investors own 95.63% of the company's stock.
About United Therapeutics
(Get Rating)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Recommended Stories
- Get a free copy of the StockNews.com research report on United Therapeutics (UTHR)
- What does Nu Holdings Stock Have To Do With Warren Buffett?
- J.B. Hunt Gets A Flat, Logistic Companies Come Into Focus
- Is Intel Stock On The Verge Of Breaking Out?
- Does it Matter Folks Aren't "Starry-Eyed" Over Pepsi's New Soda?
- Can Alaska Air Continue Soaring Above The Airline Industry?
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.